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Finding a Workable Balance
Regulation of Genetic Testing in the Human Genome Era
The Human Genome Project (HGP) will provide us with an
unprecedented view into our biological constitutions. The
genetic knowledge gained through the efforts of the HGP
is expected to facilitate diagnosis and management of
disease, guide development and use of pharmacological
agents, and offer the ability to predict disease suscepti-
bility. In the midst of this revolution, we are faced not only
with the chance to capitalize on the benefits of new
genetic knowledge, but also with the challenge of pro-
tecting individuals from potential adverse ethical, legal,
and social consequences due to their genetic identity.
Realizing the need to achieve a balance between these
benefits and risks, from its inception the HGP established
the National Institutes of Health-Department of Energy
(NIH-DOE) Joint Working Group on the Ethical, Legal,
and Social Implications of Human Genome Research
(ELSI Working Group). In early 1995, ELSI convened the
Task Force on Genetic Testing, charging it with reviewing
genetic testing in the United States and making recom-
mendations to ensure the development of safe and effec-
tive genetic tests. In its final report, published in Septem-
ber 1997 (http://www.nhgri.nih.gov/ELSI/TFGT_final/), the
Task Force concluded that, on the whole, genetic testing
was developing successfully in the United States. How-
ever, the Task Force identified several concerns about
genetic testing, including i) how genetic tests are intro-
duced into clinical practice; ii) the adequacy and appro-
priate regulation of laboratory quality assurance; iii) the
understanding of genetics by health care providers and
patients; and iv) the continued availability and quality of
testing for rare diseases. The Task Force, along with the
ELSI Working Group, also recommended the establish-
ment of an advisory panel for genetic testing. In re-
sponse, the Secretary of the Department of Health and
Human Services (DHHS) chartered, in June 1998, the
Secretary’s Advisory Committee on Genetic Testing
(SACGT) to help the DHHS formulate policies on the
development, validation, and regulation of genetic tests.
To address appropriate coordination of genetic testing
activities and policies, the SACGT was designed to in-
clude overlapping membership with the Clinical Labora-
tory Improvement Advisory Committee (CLIAC) of the
Centers for Disease Control and Prevention (CDC) and
the Medical Devices Advisory Committee of the Food and
Drug Administration (FDA). In addition to members from
CLIAC and FDA, the SACGT was formulated to have
diverse representation from academic and private
sectors, including physicians, doctoral scientists, bio-
ethicists, lawyers, and genetic counselors. The SACGT
established and maintains a website to keep the public
informed of its charter and activities (http://www4.od.
nih.gov/oba/sacgt.htm). At the first meeting of the SACGT
in June 1999, Assistant Secretary for Health and Surgeon
General Dr. David Satcher asked the Committee to as-
sess, in consultation with the public, the adequacy of
current oversight of genetic tests. As a first step, the
SACGT convened in October 1999 and held 2 days of
meetings in which public and expert testimony was heard
to provide a synopsis of current oversight of genetic
testing and ethical issues. Subsequently, the SACGT
moved to gather broader public input through a process
that involved a Federal Register notice published on De-
cember 1, 1999, a targeted mailing to 2500 individuals
and organizations, a public consultation meeting on Jan-
uary 27, 2000, and a review of the literature on oversight.
To guide public comment, the SACGT compiled and
published on its website a document titled “A Public
Consultation on Oversight of Genetic Tests,” which pro-
vided background information on genetic testing, current
oversight mechanisms, and summary recommendations
of the NIH-DOE Task Force on Genetic Testing. In the
document, the SACGT posed the following five questions
for comment:
1. What criteria should be used to assess the benefits
and risks of genetic tests?
2. How can the criteria for assessing the benefits and
risks of genetic tests be used to differentiate categories
of tests? What are the categories and what kind of
mechanism could be used to assign tests to different
categories?
3. What process should be used to collect, evaluate,
and disseminate data on single tests or groups of tests in
each category?
4. What are the options for oversight of genetic tests
and the advantages and disadvantages of each option?
5. What is the appropriate level of oversight for each
category of genetic test?
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The Clinical Practice Committee of the Association
for Molecular Pathology (AMP), in consultation with the
Executive Committee of AMP, submitted a written re-
sponse to the five questions. The AMP response, which
can be viewed in its entirety at http://www.ampweb.org/
secadvise.htm, expressed the belief that genetic testing
is a medical service with potential benefits and risks to
which the highest standards of laboratory quality assur-
ance and confidentiality must be applied, and stressed
that genetic testing should occur in the context of an
informed dialogue between patient and physician.
Further highlighted was the AMP’s view that the role of
individual genetic tests should be defined in the context
of practice guidelines for the diagnosis and management
of specific medical conditions. With regard to regulatory
oversight of genetic testing, AMP advocated continuing
to build on guidelines enunciated in the Clinical Labora-
tory Improvement Amendments of 1988 (CLIA ’88) and
those of the College of American Pathologists and Amer-
ican College of Medical Genetics. On February 24–25,
2000, the SACGT met and reviewed public input. Critical
issues raised by the public included concerns about
potential discrimination based on genetic test results and
ensuring the quality of, and access to, genetic testing.
The SACGT recently released its preliminary draft rec-
ommendations for oversight of genetic testing (http://
www4.od.nih.gov/oba/sacgt3–00final.pdf). Key features
of the draft include the recommendation that additional
oversight is warranted for all genetic tests. In a significant
departure from current oversight, the draft recommends
that “the FDA should be involved in the review of all new
genetic tests but the review should be appropriate to the
level of complexity of the information generated by the
test. The FDA should develop flexible mechanisms for
review of new genetic tests that minimize both the time
and cost of review. These mechanisms should, for exam-
ple, include the use of deemed reviewers and standards
developed in concert with professional organizations.
The FDA should give particular attention to the review of
genetic tests for predictive purposes and conditions for
which a safe and effective intervention has not been
established.” The draft also recommends that increased
knowledge of the clinical validity and utility of genetic
tests needs to be generated and that the CLIA regula-
tions should be revised to provide more specific provi-
sions for ensuring the quality of laboratories conducting
genetic tests. The draft recommendations have been
forwarded to the Assistant Secretary for Health and Sur-
geon General and the Secretary of the DHHS. The
SACGT will invite public comment on the draft and at its
next meeting, June 5–7, 2000, will review comments re-
ceived and subsequently develop a final report to be
presented to the Assistant Secretary for Health and Sur-
geon General and the Secretary of the DHHS.
The recommendations of the SACGT complement a
recently released draft Notice of Intent (NOI) formulated
by the CLIAC. The NOI serves to advise the public that
the DHHS will be preparing a Notice of Proposed Rule
Making (NPRM) to revise the CLIA regulations applicable
to laboratories that perform human genetic testing. The
NOI will be published in the Federal Register before a
60-day period for public comment. The NOI describes a
series of proposed changes that summarize the deliber-
ations of the CLIAC over the past 3 years.
Included in the proposed changes is the recommen-
dation that the definition of a molecular genetic or cyto-
genetic test be “an analysis performed on human DNA,
RNA, and chromosomes to detect heritable or acquired
disease-related genotypes, mutations, phenotypes or
karyotypes for clinical purposes. Such purposes would
include predicting risk of disease, identifying carriers,
and establishing prenatal or clinical diagnoses or prog-
noses in individuals, families, or populations.” The NOI
also contains a recommendation that laboratories per-
forming genetic testing should i) have assurance that
documented informed consent was obtained prior to ge-
netic testing, and that the consent addressed whether the
patient agreed to allow re-use of the tested specimen for
quality control and quality assurance purposes; ii) have
policies in place to protect the confidentiality of genetic
test results reporting; and iii) have a clinical consultant
associated with the laboratory qualified to provide ge-
netic counseling to the laboratory’s clients (care provid-
ers, patients, individuals). In a related development, dur-
ing the course of the SACGT meetings, a group of
individuals involved in genetic testing and oversight held
informal meetings to discuss how to assure that labora-
tory concerns about the quality of genetic testing are
appropriately addressed. This group has now been for-
malized as the CDC Genetic Forum-Laboratory Work-
group with a mission of serving as an advisory resource
to the SACGT and CLIAC in regard to implementation of
proposed changes in regulatory oversight of genetic test-
ing. Furthermore, the Laboratory Workgroup will proac-
tively endeavor to bring important genetic testing issues
to the attention of the SACGT and CLIAC and serve as a
liaison to the FDA. The next meeting of the Laboratory
Workgroup is scheduled for June 2, 2000, in Atlanta,
Georgia.
The recommendations of the SACGT and CLIAC are
occurring at a time of increased public and governmental
concern about genetic testing. A recent executive order
by President Clinton prohibits all federal departments
and agencies from using genetic information in any hiring
or promotion action. The President has endorsed the
proposed Genetic Nondiscrimination in Health Insurance
and Employment Act of 1999, introduced by Senator
Daschle and Congresswoman Slaughter, which would
extend these protections to the private sector and to
individuals purchasing health insurance. The recommen-
dations of the SACGT and CLIAC advocate additional
attention and measures in the pre- and post-analytical
phases of genetic testing. Outcomes of this may include
making the laboratories performing genetic testing re-
sponsible for maintaining documentation of informed
consent and providing comprehensive genetic counsel-
ing services. Identified in the Final Report of the Task
Force on Genetic Testing, and further highlighted by the
SACGT, was concern about how new genetic tests are
introduced into clinical practice, specifically a concern
that genetic tests may be introduced before there is
adequate knowledge of the test’s clinical validity and
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utility. The recommendation by the SACGT that the FDA
review all new genetic tests relates directly to this con-
cern and portends a paradigm shift in oversight, espe-
cially for academically based genetic testing laborato-
ries. Taken together, the proposed changes in regulatory
oversight pose new challenges that are resource-inten-
sive. Will academic clinical laboratories, in the current
fiscally restrained health care environment, be able to
identify the resources that will be needed to implement
the proposed changes and continue to serve as well-
springs for new genetic test development? Professional
organizations representing genetic testing laboratories
have arrived at a critical juncture where they must voice
their perspectives to achieve a workable balance that
allows continued and timely introduction of new genetic
discoveries into clinical practice. The Executive Council
of AMP determined that it is essential for AMP to be
represented in the CDC Genetic Forum-Laboratory Work-
group and is planning to participate in the June 2 and
subsequent meetings. Concurrently, the Clinical Practice
Committee of AMP has begun efforts to develop formal




Editor’s note: Dr. Voelkerding, President-Elect of the
Association for Molecular Pathology, has coordinated
AMP’s response to the SACGT request for information,
and will serve as the AMP’s representative to the CDC
Genetic Forum-Laboratory Workgroup.
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